These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28584008)

  • 1. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.
    Arnoult C; Brachet G; Cadena Castaneda D; Azzopardi N; Passot C; Desvignes C; Paintaud G; Heuzé-Vourc'h N; Watier H; Gouilleux-Gruart V
    J Immunol; 2017 Jul; 199(2):418-424. PubMed ID: 28584008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
    Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
    van Schie KA; Hart MH; de Groot ER; Kruithof S; Aarden LA; Wolbink GJ; Rispens T
    Ann Rheum Dis; 2015 Jan; 74(1):311-4. PubMed ID: 25342759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A
    Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
    Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
    Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab.
    Suzuki T; Tada M; Ishii-Watabe A
    Biologicals; 2020 Jan; 63():39-47. PubMed ID: 31883741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
    Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.
    Ara-Martín M; Pinto PH; Pascual-Salcedo D
    J Dermatolog Treat; 2017 Nov; 28(7):606-612. PubMed ID: 28274164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.
    Homann A; Röckendorf N; Kromminga A; Frey A; Platts-Mills TA; Jappe U
    Theranostics; 2017; 7(19):4699-4709. PubMed ID: 29187897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.